Skip to main content
OpenTrials
Completed

NCT Number: NCT02295514

Correlation Between PTP1B Expression and Organ Failure During Sepsis

Despite major advances in the treatment and understanding of the pathophysiological mechanisms, mortality of severe sepsis remains high, ranging from 25 to 50%. With a prevalence > 20% in intensive care units, it is now in a population increasingly aging with many co-morbidities, a real public health problem. Thus, changes in treatment to physiological axes could change the prognosis of these patients. Protein Tyrosine Phosphatase 1B (PTP1B) is involved in the negative regulation of many cellular pathways such as the response to insulin, leptin and certain growth factors and endothelial nitric oxide production. PTP1B appears to be particularly involved in the control of endothelial function and insulin secretion. Under these conditions, encouraging results have been obtained in a model of insulin resistance (obesity, diabetes) and as part of pro-angiogenic therapy by inhibition of PTP1B on models of heart failure. Recent advances have broadened the pathophysiological implications of PTP1B conferring a potential role in the regulation of inflammatory processes. In an experimental model of septic shock (Inserm 1096), the investigators demonstrated a significant improvement in survival and cardiovascular function in genetically deficient mice PTP1B (PTP1B - / -). Finally, PTP1B is involved in the downregulation of the signaling pathway of insulin via a feedback phenomenon. Septic shock induces many changes in carbohydrate metabolism. These changes result in hyperglycemia associated with insulin resistance, an independent risk factor of morbidity and mortality. Taken together, these data suggest that the expression of PTP1B could be useful in septic patients by modulating insulin resistance and thus the prognosis of these patients. This justifies the investigator clinical research project on the relationship between the expression of PTP1B levels, glycemic status and prognosis evaluated by the SOFA score in patients with septic shock with multiple organ failure.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rouen University Hospital

Rouen, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients in ICU for septic shock
  • Person belonging to a social security system
  • Informed patient who signed consent
  • Contraceptive method in women of reproductive age

Exclusion criteria

  • Pregnancy
  • Patient not able to take a decision because of an administrative or legal decision
  • Patient participating to an other interventional study
  • BMI > 30 kg/m2
  • Diabetes with specific treatment

Treatment and study plan

PTP1B dosage

Biological

PTP1B sampled and dosed during sepsis

Primary outcomes

  1. Change from baseline in PTP1B level expression

    Time frame: Day 5

    Change from baseline in PTP1B level expression by biological analysis

  2. Number of patients with organ failure

    Time frame: Day 5

    Number of patients with organ failure

Secondary outcomes

  1. Dose of insulin administered during the sepsis

    Time frame: Day 5

    cumulative dose of insulin administered in the first 5 days of hospitalization

  2. Insulin resistance evaluation

    Time frame: Day 1

    Evaluation of insulin resistance by biological analysis

  3. Blood glucose Analysis

    Time frame: Day 5

    Analysis of the variability in Blood glucose

  4. Number of death participants at ICU discharge

    Time frame: ICU discharge, day 28

    ICU mortality at day 28

  5. Number of death participants at at the end of the study

    Time frame: Day 28

    Mortality at day 28

  6. Number of death participants at at hospital discharge

    Time frame: 10 days (average)

    Mortality at hospital discharge, average of 10 days after surgical intervention

  7. Duration of mechanical ventilation

    Time frame: Day 28

    Duration of mechanical ventilation from admission to discharge

Sponsors and collaborators

Lead sponsor

University Hospital, Rouen

Other

Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

Registry information

Acronym: SEPP1B

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Nov 20, 2014
Registry last updated
May 12, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.